Ruchi Gupta (Scientist I) from MedImmune joins the brand-new Device Development stream to talk about the current bio-therapeutics focus on the molecular targets expressed on cells/tumors
Inspite of increased antigen expression on the targeted organ, less than 10% of the IV administrated biologics can reach the diseased tissues. Tissue targeting using caveolae proteins can allow for specific delivery to organs of interest within minutes to hours. This talk will focus on caveolae technology to specifically deliver to lungs and kidneys and improve drug efficacy. This technology can achieve markedly improved efficacy of drugs in several diseases including fibrosis, COPD, infections as well as tumors.
More information available on the programme